Literature DB >> 11393506

Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept.

M Baghai1, D R Osmon, D M Wolk, L E Wold, G J Haidukewych, E L Matteson.   

Abstract

Patients with long-standing, severe, erosive rheumatoid arthritis who have extra-articular manifestations and have undergone joint replacement surgery are at increased risk for serious infection and premature mortality. New therapies, including cytokine antagonists, hold great promise for improving the course of rheumatoid arthritis. However, they have powerful anti-inflammatory effects that may mask symptoms of serious infection. We report a case of fatal pneumococcal sepsis occurring in a 37-year-old woman with rheumatoid arthritis treated with the tumor necrosis factor antagonist etanercept and suggest management strategies for early detection and management of this complication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11393506     DOI: 10.4065/76.6.653

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  27 in total

Review 1.  Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Authors:  Annette Langer-Gould; Lawrence Steinman
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 2.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

3.  Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome.

Authors:  Paola Sabrina Buonuomo; Andrea Campana; Antonella Insalaco; Claudia Bracaglia; Manuela Pardeo; Elisabetta Cortis
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

Review 4.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

5.  Prevalence and clinical characteristics of tuberculosis in rheumatoid arthritis patients.

Authors:  Fadoua Allali; Hanane Rkain; Afaf Faik; Selma El Hassani; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2004-12-03       Impact factor: 2.980

6.  Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis.

Authors:  Christian Zimmer; Martin Beiderlinden; Jürgen Peters
Journal:  Clin Rheumatol       Date:  2005-10-01       Impact factor: 2.980

7.  Trends in serious infections in rheumatoid arthritis.

Authors:  Orla M Ni Mhuircheartaigh; Eric L Matteson; Abigail B Green; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

8.  Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand.

Authors:  Nagamani Vunnam; Sophia Szymonski; Petra Hirsova; Gregory J Gores; Jonathan N Sachs; Benjamin J Hackel
Journal:  Biochemistry       Date:  2020-09-30       Impact factor: 3.162

9.  Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis.

Authors:  H Schotte; B Schlüter; S Drynda; P Willeke; N Tidow; G Assmann; W Domschke; J Kekow; M Gaubitz
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

10.  Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis.

Authors:  Tulin Cagatay; Munevver Aydin; Sule Sunmez; Penbe Cagatay; Ziya Gulbaran; Ahmet Gul; Bahar Artim; Zeki Kilicaslan
Journal:  Rheumatol Int       Date:  2009-10-21       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.